{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:16:21Z","timestamp":1770048981979,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes mellitus (T2DM) and may influence reward-related pathways, suggesting potential effects on nicotine dependence and smoking-related outcomes. Randomized evidence in patients with T2DM remains limited. This trial evaluates the effects of GLP-1RAs on nicotine dependence and smoking exposure and explores potential neural mechanisms using functional MRI (fMRI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This single-center, parallel-group randomized controlled trial will enroll 46 male adults with T2DM who are current smokers with Fagerstr\u00f6m Test for Nicotine Dependence (FTND) score \u22654. Participants will be randomized (1:1) to receive a GLP-1RA or a dipeptidyl peptidase-4 inhibitor (DPP-4i) for 24 weeks as part of routine glucose-lowering therapy optimization. No structured smoking cessation counseling or smoking cessation pharmacotherapy will be provided by the research team. The primary endpoint is change in FTND score from baseline, assessed at weeks 1, 4, 8, 12, and 24. Secondary endpoints include changes in exhaled carbon monoxide (CO) and smoking cessation rate at weeks 12 and 24, and changes in metabolic parameters. Exploratory endpoints include changes in resting-state fMRI measures from baseline to week 24 and their associations with smoking- and metabolic-related outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial status<\/jats:title>\n                    <jats:p>Recruitment started in June 2025 and is ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , identifier (NCT06924697).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcdhc.2026.1665837","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:15:39Z","timestamp":1770009339000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of glucagon-like peptide-1 receptor agonists on cigarette smoking consumption in type 2 diabetes patients: study protocol of a randomized, parallel -controlled clinical trial"],"prefix":"10.3389","volume":"7","author":[{"given":"Da","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinnan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/30.3.547","article-title":"Cigarette smoking and glycaemia: the EPIC-Norfolk Study. European Prospective Investigation into Cancer","volume":"30","author":"Sargeant","year":"2001","journal-title":"Int J Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/14799731241291538","article-title":"Smoking-related interstitial lung disease: A narrative review","volume":"21","author":"Casal","year":"2024","journal-title":"Chron Respir Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1027","article-title":"Pancreatic cancer risk in relation to lifetime smoking patterns, tobacco type, and dose-response relationships","volume":"29","author":"Molina-Montes","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21231","article-title":"Tobacco use and cessation for cancer survivors: an overview for clinicians","volume":"64","author":"Karam-Hage","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19480","DOI":"10.1038\/s41598-020-76556-7","article-title":"The effect of smoking on chronic inflammation, immune function and blood cell composition","volume":"10","author":"Elisia","year":"2020","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12070144","article-title":"Effects of combustible cigarettes and heated tobacco products on systemic inflammatory response in patients with chronic inflammatory diseases","volume":"12","author":"Kastratovic","year":"2024","journal-title":"Diseases"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2009.09.003","article-title":"Smoking and diabetes--the double health hazard","volume":"3","author":"Fagard","year":"2009","journal-title":"Primary Care Diabetes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-016-0059-9","article-title":"Sex and estrogens alter the action of glucagon-like peptide-1 on reward","volume":"7","author":"Richard","year":"2016","journal-title":"Biol Sex Differ"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7326\/M23-2718","article-title":"Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using real-world data","volume":"177","author":"Wang","year":"2024","journal-title":"Ann Intern Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2014.01.006","article-title":"Sex differences in resting state neural networks of nicotine-dependent cigarette smokers","volume":"39","author":"Wetherill","year":"2014","journal-title":"Addict Behav"},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pscychresns.2017.04.011","article-title":"Functional network connectivity predicts treatment outcome during treatment of nicotine use disorder","volume":"265","author":"Wilcox","year":"2017","journal-title":"Psychiatry Res Neuroimaging"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2009.07.006","article-title":"Static and dynamic characteristics of cerebral blood flow during the resting state","volume":"48","author":"Zou","year":"2009","journal-title":"Neuroimage"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntaf005","article-title":"Exploring predictors of treatment response to GLP-1 receptor agonists for smoking cessation","volume":"27","author":"Yammine","year":"2025","journal-title":"Nicotine Tob Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01021-1","article-title":"Glucagon-like peptide 1 receptor agonist (GLP1RA) exposure and outcomes in type 2 diabetes: A systematic review of population-based observational studies","volume":"12","author":"Caparrotta","year":"2021","journal-title":"Diabetes Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2025.03.003","article-title":"Structural pharmacology and mechanisms of GLP-1R signaling","volume":"46","author":"Zhou","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13030136","article-title":"Mechanisms of GLP-1 in modulating craving and addiction: neurobiological and translational insights","volume":"13","author":"Amorim Moreira Alves","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2013.00181","article-title":"The central GLP-1: implications for food and drug reward","volume":"7","author":"Skibicka","year":"2013","journal-title":"Front Neurosci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192013222","article-title":"The effect of smoking cessation on body weight and other metabolic parameters with focus on people with type 2 diabetes mellitus","volume":"19","author":"Driva","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00720","article-title":"The insula: A brain stimulation target for the treatment of addiction","volume":"10","author":"Ibrahim","year":"2019","journal-title":"Front Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2019.06.002","article-title":"The insula in nicotine use disorder: Functional neuroimaging and implications for neuromodulation","volume":"103","author":"Regner","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab015","article-title":"Sex differences in the association of cigarette craving with insula structure","volume":"24","author":"Perez Diaz","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.48","article-title":"Cigarette exposure, dependence, and craving are related to insula thickness in young adult smokers","volume":"39","author":"Morales","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.134","article-title":"Association between nicotine dependence severity, BOLD response to smoking cues, and functional connectivity","volume":"38","author":"Claus","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01528-0","article-title":"Nicotine dependence and insula subregions: functional connectivity and cue-induced activation","volume":"48","author":"Ghahremani","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1369-1600.2012.00507.x","article-title":"Neural correlates of attentional bias for smoking cues: modulation by variance in the dopamine transporter gene","volume":"19","author":"Wetherill","year":"2014","journal-title":"Addict Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301371","article-title":"Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study","volume":"32","author":"Franklin","year":"2007","journal-title":"Neuropsychopharmacology"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1665837\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:15:39Z","timestamp":1770009339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1665837\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":32,"alternative-id":["10.3389\/fcdhc.2026.1665837"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2026.1665837","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"article-number":"1665837"}}